An experimental DUAL model of advanced liver damage by Benedé-Ubieto, R. (Raquel) et al.
1051
Hepatology CommuniCations, Vol. 5, no. 6, 2021  
An Experimental DUAL Model of 
Advanced Liver Damage
Raquel Benedé- Ubieto,1,2 Olga Estévez- Vázquez,1,2* Feifei Guo,2* Chaobo Chen ,2 Youvika Singh,3 Helder I. Nakaya,3,4   
Manuel Gómez del Moral ,5 Arantza Lamas- Paz,2 Laura Morán,2 Nuria López- Alcántara,2,6 Johanna Reissing,7 Tony Bruns,7 
Matías A. Avila ,8-10 Eva Santamaría,8,9 Marina S. Mazariegos,2 Marius Maximilian Woitok,7 Ute Haas,7 Kang Zheng,2,11,12 
Ignacio Juárez,2 José Manuel Martín- Villa,2,13 Iris Asensio,9,13,14 Javier Vaquero ,9,13,14 Maria Isabel Peligros,15   
Josepmaria Argemi,16-18 Ramón Bataller ,16,19 Javier Ampuero,9,20 Manuel Romero Gómez ,9,20 Christian Trautwein,7 
Christian Liedtke ,7 Rafael Bañares,2,9,13,14 Francisco Javier Cubero ,2,11** and Yulia A. Nevzorova 2,7,11**
Individuals exhibiting an intermediate alcohol drinking pattern in conjunction with signs of metabolic risk present clini-
cal features of both alcohol- associated and metabolic- associated fatty liver diseases. However, such combination remains 
an unexplored area of great interest, given the increasing number of patients affected. In the present study, we aimed 
to develop a preclinical DUAL (alcohol- associated liver disease plus metabolic- associated fatty liver disease) model in 
mice. C57BL/6 mice received 10% vol/vol alcohol in sweetened drinking water in combination with a Western diet for 
10, 23, and 52  weeks (DUAL model). Animals fed with DUAL diet elicited a significant increase in body mass index 
accompanied by a pronounced hypertrophy of adipocytes, hypercholesterolemia, and hyperglycemia. Significant liver 
damage was characterized by elevated plasma alanine aminotransferase and lactate dehydrogenase levels, extensive he-
patomegaly, hepatocyte enlargement, ballooning, steatosis, hepatic cell death, and compensatory proliferation. Notably, 
DUAL animals developed lobular inflammation and advanced hepatic fibrosis. Sequentially, bridging cirrhotic changes 
were frequently observed after 12  months. Bulk RNA- sequencing analysis indicated that dysregulated molecular path-
ways in DUAL  mice were similar to those of patients with steatohepatitis. Conclusion: Our DUAL model is character-
ized by obesity, glucose intolerance, liver damage, prominent steatohepatitis and fibrosis, as well as inflammation and 
fibrosis in white adipose tissue. Altogether, the DUAL model mimics all histological, metabolic, and transcriptomic 
gene signatures of human advanced steatohepatitis, and therefore serves as a preclinical tool for the development of 
therapeutic targets. (Hepatology Communications 2021;5:1051-1068).
Excessive alcohol drinking is a leading cause of chronic liver disease and accounts for up to 60%- 80% of liver- related mortality in Europe.(1) 
These data become even more relevant considering that 
alcohol- associated liver disease (ALD) receives only 
about 5% of the attention in the field of hepatology.(2)
The principal fact that only about 6%- 30% of heavy 
drinkers develop cirrhosis indicates that additional 
factors modulate the risk of ALD progression.(1) 
Clinical observations commonly suggest a wide indi-
vidual susceptibility, and indicate several risk factors 
for ALD including drinking patterns, female gen-
der, genetic background, cigarette smoking, occu-
pational hazards, and hepatotropic viruses. Obesity 
and metabolic syndrome (MS) represent another 
important group of risk factors that accelerate fibrosis 
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progression, hepatic carcinogenesis, and mortality in 
ALD.(3) Epidemiological studies using a large cohort 
of patients(4- 6) clearly showed that obese patients with 
alcoholism have 2- 3- times higher risk of developing 
steatohepatitis and progression to fibrosis or cirrho-
sis. Hence, obese individuals consuming 15 or more 
drinks per week have an adjusted relative rate of liver- 
related death of 18.9 compared with 3.16 in their lean 
counterparts.(5)
However, the patients with intermediate levels of 
ethanol use plus the presence of metabolic risks (i.e., 
dual clinical features of ALD and metabolic associ-
ated fatty liver disease [MAFLD]) represent a large 
understudied area in hepatology with a huge unmet 
need in preclinical and clinical studies.(7)
Herein we report a physiological, innovative exper-
imental DUAL (ALD plus MAFLD) model that 
synergistically combines the effects of alcohol and 
Western diet (WD). The taste of alcohol was cam-
ouflaged by adding glucose to the drinking water, 
consequently increasing the daily ethanol (EtOH) 
consumption and remarkably intensifying liver dam-
age. Within 23  weeks, this preclinical DUAL model 
reproduced all of the key metabolic and histological 
features of human steatohepatitis, with consistent 
development of hepatic fibrosis, enhanced obesity, 
glucose intolerance, as well as inflammation of white 
adipose tissue (WAT). Altogether, this preclinical 
model might be well- considered as a useful experi-
mental model to study the dangerous combination of 
ALD plus MAFLD in human, and therefore be fur-
ther used for the development of therapeutic options.
Materials And Methods
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law, and approved by the authority of environment 
conservation and consumer protection of the Regional 
Government of Madrid (PROEX210/18). All ani-
mals were maintained in the Animal Facility at the 
Faculty of Biology, Complutense University Madrid, 
in a temperature- controlled room with 12- hour light/
dark cycle with free access to food and water accord-
ing to the guidelines of the Federation for Laboratory 
Animal Science Associations.
animal eXpeRimentation
Female 10- week- old C57BL6/J mice were ran-
domly assigned to four different experimental groups. 
The total number of mice per group was five to 
seven. Mice were treated with a DUAL diet con-
sisting of WD (D09100301; Research Diets, Inc., 
New Brunswick, NJ) and 10% vol/vol EtOH abso-
lute in sweetened drinking water containing 6.75% 
D- glucose (Sigma- Aldrich, St. Louis, MO). Controls 
were fed with either normal diet only (Altomin, Lage, 
Germany), WD only, or EtOH in sweetened drinking 
water only (Supporting Tables S1- S3).
statistiCal analysis
Data are expressed as mean  ±  SD. GraphPad 
Prism version 8.0 (https://www.graph pad.com/
scien tific - softw are/prism/) (San Diego, CA) was used 
for statistical analysis and graph design. Statistical 
significance was determined by one- way analysis of 
variance ANOVA followed by a Tukey post hoc test. 
One- way paired ANOVA followed by Bonferroni’s post 
hoc test was used to evaluate the differences between 
10- week and 23- week feeding groups. Values with dif-
ferent superscripts are significantly different from each 
other (P  <  0.05), as assessed by one- way ANOVA. 
Differences (P < 0.05) between time points (10 weeks 
vs. 23 weeks) for each pairing group were assessed by 
pairing one- way ANOVA and denoted by “#.”
Results
CHaRaCteRiZation oF a 
pReCliniCal Dual moDel
Because low EtOH intake due to natural aversion 
in mice is the main limiting factor for ALD devel-
opment,(8) we masked the taste of alcohol by adding 
6.75% D- glucose to the drinking water and gradually 
increased EtOH concentration from 1% to 10% vol/
vol. Mice usually consume alcohol up to 25% vol/vol.(9) 
Thus, initially we performed a pilot study to assess 
the optimal concentration of EtOH in the drinking 
water. Surprisingly we found that the concentration 
of EtOH significantly affected the volume, and, con-
sequently the quantity of the daily consumed etha-
nol. As the concentration of EtOH increased (20%), 
the mice drank less volume, and intake significantly 
decreased. At a 5% concentration, the quantity of 
consumed EtOH remained relatively low (Supporting 
Fig.  S1A). Only a concentration of 10% vol/vol of 
EtOH resulted in severe pathophysiologic changes 
(Supporting Fig.  S1B,C). Consequently, for all of 
the following experiments, animals were randomly 
assigned to four groups: (1) control group; (2) WD 
plus sweetened water group; (3) 10% vol/vol EtOH in 
sweetened water plus chow diet group; and (4) DUAL 
group (Supporting Fig. S2A).
oBesity, DyslipiDemia, anD 
glyCemia: FeatuRes oF tHe 
Dual Diet
Body weight (BW) increased steadily in all treated 
groups throughout the experimental period (Fig.  1A 
[left] and Supporting Table  S4). Previous studies in 
both humans and rodents showed significantly elevated 
EtOH intake in subjects consuming fat.(10) Consistently, 
our model nicely reflected this positive correlation, as 
DUAL- fed animals demonstrated greater EtOH intake 
compared with the EtOH- fed group (Supporting 
Fig. S3A). In turn, alcohol stimulated the ingestion of 
a fat- rich diet, thus creating a positive feedback loop 
(Supporting Fig.  S3B). This finally resulted in higher 
daily caloric consumption (Fig.  1A [middle panel]) 
and robust increase in the body mass index (BMI) in 
DUAL- fed mice (Fig. 1A [right panel]).
Obesity and ALD are associated with profound 
changes in the function of adipose tissue, which has 
important systemic and hepatic consequences.(11) 
The morphometric evaluation of adipocytes in WAT 
from visceral fat pad showed that DUAL diet led to 
an increase in adipocyte size by 93.2% after 23 weeks 
of feeding (Fig.  1B and Supporting Fig.  S4A). 
Additionally, many crown- like structures, formed by 
macrophages aggregated around dying adipocytes, 
were observed in the DUAL group (Fig.  1B). These 
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results were confirmed by a trend toward increased 
F4/80 and CD45 positive cell infiltration of WAT in 
DUAL- fed animals (Fig. 1C).
Excessive amounts of extracellular matrix (ECM) 
and fibrosis in WAT accelerates adipose tissue dys-
function in obese individuals.(12) Consistently, sirius 
red (SR) staining revealed that DUAL diet dramati-
cally increased collagen deposition in WAT compared 
with the rest of the experimental groups (Fig. 1D and 
Supporting Fig. S4B).
Obesity is strongly associated with other features of 
MS, including glycemia and dyslipidemia.(13) In fact, 
the circulating levels of total cholesterol were con-
stantly higher in DUAL- fed animals (10  weeks and 
23  weeks) compared with control groups (Fig.  1E). 
Additionally, DUAL- fed mice developed hyperglyce-
mia at 10  weeks that was sustained up to 23  weeks 
of treatment (Fig.  1F). Hence, no significant dif-
ference between control animals and treated ones 
was detected by glucose tolerance test. Insulin toler-
ance test (ITT) after 6  hours of fasting showed the 
impaired insulin sensitivity only in WD and EtOH 
groups (Supporting Fig. S5A,B).
Dual FeeDing tRiggeRs 
Hepatomegaly anD Fatty 
liVeR Disease
Obesity and MS predispose to the development 
of fatty liver disease.(14) After 23  weeks of DUAL 
diet, animals exhibited enlarged livers, which were 
pale and yellowish in color, indicating lipid accumu-
lation (Fig.  2A [left]). Accordingly, the hepatic mass 
was increased, and the hepatosomatic ratio of DUAL 
mice reached almost 8.5% (Fig. 2A [middle and right 
panels]). Hepatocytes of DUAL- fed animals lost their 
typical hexagonal shape and became enlarged round 
cells, as demonstrated by phalloidin staining (Fig. 2B).
Blinded quantitative analysis performed by an 
experienced pathologist revealed that animals treated 
with DUAL diet exhibited microvesicular and mac-
rovesicular  steatosis  grade 2 associated with hepato-
cyte ballooning, reaching in most of the animals 
a S2A4 NAFLD score (moderate steatosis, severe 
activity according to Bedossa system(15)) (Fig. 2C and 
Supporting Fig. S6A- C).
All experimental groups after 23  weeks of treat-
ment displayed positive Oil Red O (ORO) staining 
compared with control mice. However, numerous 
macrolipid and microlipid droplets were more profuse 
in DUAL- fed mice (Fig.  2D). Consistently, hepatic 
triglycerides (TG) were increased in all mice, with the 
highest levels found in those treated with DUAL diet 
(Supporting Fig S6D).
Dietary free fatty acids (FFAs) are the main source 
of TG in the liver. Interestingly, while the level of non-
esterified fatty acids (NEFAs) in the serum of WD- 
fed mice was significantly increased, the NEFAs in the 
DUAL animals were not up- regulated (Supporting 
Fig.  S6E). This indicates the massive FFA flux 
into the liver. Consistently we found significant up- 
regulation of CD36 expression (FA translocase) in the 
livers of DUAL animals (Supporting Fig.  S6F). At 
the same time, the level of TG in serum of DUAL 
mice was not proportionally increased, reflecting the 
possible impairment in hepatic secretion of very low- 
density lipoproteins(16) (Supporting Fig. S6G).
Expectedly, the lipid load induced an increase in 
lipid oxidation, as observed by raised carnitine palmi-
toyltransferase 1c (CPT- 1c) levels in WD. However, 
protein expression of CPT- 1c in the DUAL group 
was not as high as in WD mice. Altogether, high FFA 
flux into the liver, poor TG secretion, in combination 
with reduced lipid oxidation contributed to accumula-
tion of a remarkable amount of fat in the liver paren-
chyma of DUAL mice (Fig. 2E).
Fig. 1. Metabolic profile of mice treated with DUAL diet and control groups. (A) Left: BW curve during the feeding period. Statistical 
differences between DUAL and control groups are shown (n = 5- 7). Differences (P < 0.05) between control and DUAL group are denoted 
by “*.” Middle: Calorie intake per day including calories in food and in drinking water (D- glucose and/or EtOH) (n = 4- 6). Right: BMI 
was calculated after 10 and 23 weeks of feeding (body surface area [m2/BW]; n = 5- 9). (B) Representative WAT H&E. Scale bar = 100 µm 
(n = 3). (C) Representative CD45 and F4/80 IF staining of WAT. Positive immune cells are stained in green. Nuclei are stained in blue 
using DAPI as a counterstain. Scale bar = 100 µm (n = 3). (D) SR staining performed in WAT. Scale bar = 100 µm (n = 3). (E) Levels 
of cholesterol in serum (n = 5- 7). (F) Basal glucose levels in blood after 12 hours of fasting (n = 3). Values with different superscripts are 
significantly different from each other (P < 0.05), assessed by one- way ANOVA. Differences (P < 0.05) between time points (10 weeks vs. 
23 weeks) for each pairing group were assessed by pairing one- way ANOVA and denoted as “#.” Abbreviation: DAPI, 4′,6- diamidino- 2- 
phenylindole.
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oXiDatiVe stRess anD 
HepatoCyte Cell DeatH in 
Dual- FeD miCe
Extensive fat accumulation in the liver tissue 
together with alcohol consumption generate oxi-
dative stress.(17) Immunoblotting showed increased 
expression of cytochrome P450 in the DUAL group 
after 23  weeks feeding (Fig.  3A). Consequently, we 
performed 4- hydroxinonenal staining in all groups of 
mice. Overall, DUAL diet led to significant induction 
of lipid peroxides in the liver (Fig. 3B).
Oxidative stress led to significant ultrastructural 
morphological changes in DUAL animals identi-
fied by transmission electron microscopy (TEM).(18) 
After 23  weeks, DUAL diet promoted important 
morphological changes in mitochondria, which exhib-
ited irregular circled shapes, accumulation of cris-
tae, and multiple electron dense particles (Fig.  3C). 
Importantly, enlargement of the rough endoplasmic 
reticulum and cisternae dilation were specifically found 
in DUAL mice (Fig. 3C and Supporting Fig. S7A,B).
Oxidative and mitochondrial stress likely con-
tributed to liver damage and caused modest but 
significant increases of the plasma levels of alanine 
aminotransferase (ALT), aspartate aminotransferase 
(AST), lactate dehydrogenase (LDH), all major clin-
ical indicators of cellular liver injury (Fig.  3D and 
Supporting Fig.  S7C). Consistently, the cell death 
by TUNEL (terminal deoxynucleotidyl transferase– 
mediated deoxyuridine triphosphate nick- end label-
ling) staining in DUAL- fed livers was significantly 
higher compared with other experimental groups 
(Fig. 3E and Supporting Fig. S7D).
Death of hepatocytes may trigger compensatory 
proliferation in surrounding cells to maintain tissue 
homeostasis. Accordingly, Ki- 67 staining revealed that 
cellular proliferation was higher in DUAL mice com-
pared with the rest of experimental groups (Fig.  3F 
and Supporting Fig. S7E).
Dual FeeDing inDuCes 
eXtensiVe HepatiC 
inFlammation
Fat accumulation and cell death in the liver further 
caused immune cell infiltration and hepatic inflam-
mation.(19) All treated groups showed an increased 
accumulation of CD45 and F4/80 positive Kupffer 
cells/macrophages, as assessed by immunofluores-
cence (IF) staining, but such infiltration was clearly 
more pronounced in DUAL animals (Fig. 4A- C and 
Supporting Fig. S8A,B).
Neutrophil infiltration is an important hallmark 
of alcoholic hepatitis and correlates with the severity 
of disease.(20) Immunohistochemistry (IHC) stain-
ing revealed that neutrophil infiltration in the liver 
was significantly higher in DUAL mice (Supporting 
Fig.  S8C,D). Infiltrating cells actively produce dif-
ferent cytokines and further contribute to create a 
pro- inflammatory microenvironment. Consistently, 
messenger RNA (mRNA) expression of tumor necro-
sis factor- α (TNF- α) was significantly increased in 
mice fed with DUAL diet, especially after 23  weeks 
of feeding (Fig. 4D).
Dual Diet leaDs to inCReaseD 
HepatiC stellate Cell 
aCtiVation anD HepatiC 
FiBRogenesis
TNF- α overproduction induces activation of 
hepatic stellate cells (HSCs) in the liver.(21) We 
found strong expression of α- smooth muscle actin (α- 
SMA), a marker of HSCs activation, using western 
blot analysis and IHC staining in DUAL- fed animals 
(Fig.  5A,B [upper panel]). Activated HSCs are the 
major source of ECM during progression of fibro-
sis.(22) Hence, SR staining clearly demonstrated that 
feeding a WD or EtOH alone induced only minor 
collagen expression in the liver, whereas rapid and 
Fig. 2. DUAL mice develop hepatomegaly and advanced steatosis. (A) Left: Liver macroscopic images after 23 weeks of feeding. Middle: 
Liver weight (g) (n = 5- 7). Right: Liver weight– to- BW ratio (%) (n = 5- 7). (B) Representative phalloidin- stained liver images and size 
of hepatocytes in phalloidin- stained liver pictures quantified by ImageJ software. Scale bar = 100 µm (n = 3). (C) H&E representative 
images after 10 weeks or 23 weeks of feeding. Scale bar = 100 µm. Steatosis score assigned after 23 weeks of treatment (n = 3- 7). (D) 
Illustrative ORO- stained liver sections from each group and time- point feeding. Scale bar = 100 µm. Quantification of ORO- stained area 
(n = 3). (E) CPT- 1c immunoblot using GAPDH as loading control. Ratio between CPT- 1c and GAPDH was calculated. Values with 
different superscripts are significantly different from each other (P < 0.05), assessed by one- way ANOVA. Differences (P < 0.05) between 
time points (10 weeks vs. 23 weeks) for each pairing group were assessed by pairing one- way ANOVA and denoted as “#.” Abbreviation: 
GAPDH, glyceraldehyde 3- phosphate dehydrogenase.
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severe progression of fibrosis was a notable histo-
logical feature of DUAL- fed mice. The first signs of 
fibrosis were detectable as soon as 10 weeks of treat-
ment (Supporting Fig. S9A,B), with remarkable esca-
lation of fibrogenesis at 23 weeks (Fig. 5B,C [middle 
panel]). These findings were additionally confirmed by 
IF staining for collagen I (Fig.  5B,D [lower panel]). 
Histopathological evaluation of fibrosis revealed F1a 
stage after 10  weeks and F1b in all DUAL animals 
after 23 weeks of feeding (Fig. 5E). Additionally, col-
lagen fibers were further identified though TEM anal-
ysis in DUAL mice (Supporting Fig.  S10). Finally, 
Fig. 3. DUAL diet stimulates early oxidative stress and hepatocyte cell death. (A) CYP2E1 western blot, β- actin used as a loading control. 
Ratio between CYP2E1 and β- actin was calculated. (B) Illustrative 4- HNE- stained liver sections from each group after 23 weeks of feeding 
and 4- HNE quantification (n = 3). Scale bar = 100 µm. (C) Representative TEM pictures of control and DUAL groups. Mitochondria and 
endoplasmic reticulum are shown. Arrows mark cristae inclusions in mitochondrial matrix. (D) ALT and LDH measurements in serum 
after 12 hours of fasting (n = 5- 7). (E) Representative TUNEL- stained photomicrographs at 23 weeks. Scale bar = 100 µm. (F) Ki- 67 
liver IHC staining after 23 weeks of feeding. Scale bar = 100 µm. Values with different superscripts are significantly different from each 
other (P < 0.05), assessed by one- way ANOVA. Abbreviations: 4- HNE, 4- hydroxinonenal; CYP2E1, cytochrome P450; ER, endoplasmic 
reticulum; TUNEL, terminal deoxynucleotidyl transferase– mediated deoxyuridine triphosphate nick- end labeling.
Fig. 4. DUAL mice manifest enhanced hepatic inflammation. (A) Illustrative CD45 and F4/80 IF staining in liver sections of mice fed 
for 23 weeks. Positive immune cells are stained in green. Nuclei are stained in blue using DAPI as a counterstain. Arrows indicate CD45 
or F4/80 positive cells, respectively. Scale = 100 µm. (B,C) Quantification of %CD45 and F4/80 positive cells, respectively, using ImageJ 
software (n = 3). (D) TNF- α mRNA relative expression to GAPDH after 10 weeks and 23 weeks on diet (n = 3- 6). Values with different 
superscripts are significantly different from each other (P < 0.05), assessed by one- way ANOVA. Abbreviations: DAPI, 4′,6- diamidino- 2- 
phenylindole; GAPDH, glyceraldehyde 3- phosphate dehydrogenase.
Hepatology CommuniCations, June 2021BENEDÉ- UBIETO, ESTÉVEZ- VÁZQUEZ, ET AL.
1060
Hepatology CommuniCations, Vol. 5, no. 6, 2021 BENEDÉ- UBIETO, ESTÉVEZ- VÁZQUEZ, ET AL.
1061
quantitative polymerase chain reaction confirmed 
that DUAL treatment significantly up- regulated 
pro- fibrogenic genes such as collagen1α1 and MCP1 
(monocyte chemoattractant protein 1) (Fig. 5F).
Dual Diet DRiVes 
tHe aCtiVation oF 
CHaRaCteRistiC   
Disease- assoCiateD   
signaling patHWays
To better define the relevance of the DUAL model 
and to unveil potential modulation of cell regula-
tory processes, the livers of 10- week- old DUAL mice 
were subjected to bulk RNA sequencing (RNA- seq). 
A total of 1,563 genes were significantly (adjusted P 
value < 0.05 and fold change > 2) altered in liver after 
DUAL feeding compared with the corresponding con-
trols, of which 1,259 were up- regulated and 304 down- 
regulated (Fig.  6A). Differentially expressed mRNAs 
were predominantly enriched in inflammation, fibrosis, 
and metabolism- related pathways. Affected inflam-
matory pathways ranged from inflammatory response, 
neutrophil- mediated immunity and activation, chemo-
kine and cytokine biosynthesis and activity, and phago-
cytic and platelet activation. The fibrotic pathways 
included ECM organization, collagen fibril organi-
zation, and collagen binding (Fig.  6B). Furthermore, 
pathway analysis was performed with reference to the 
Kyoto Encyclopedia of Genes and Genomes database 
(Supporting Fig.  S11), and, consistently, DUAL ani-
mals showed an up- regulation of important metabolic/
inflammatory/fibrogenic pathways including phospho-
inositide 3- kinase (PI3K)/AKT, TNF, nuclear factor 
kappa B NF- κB, CAMs, ECM interaction, focal adhe-
sion, chemokine, and toll- like receptor (TLR) signaling 
pathways. Additionally, protein– protein interaction net-
works were built using the differentially expressed genes 
(Fig.  6C). The results indicate the presence of central 
regulatory genes coordinating the expression of many 
others. Most of these genes are involved in inflammatory 
response (Btk [Bruton’s tyrosine kinase], Csf1r [colony 
stimulating factor 1 receptor], Ifr8 [interferon regulatory 
factor 8], Syk, and Nlrp3 [NLR family pyrin domain 
containing 3]), apoptosis and cell cycle regulation (Bcl2 
[B cell lymphoma 2], Plcg2 [phospholipase C gamma 
2], and Fyn), and metabolism (Pik3 [phosphoinositide 
3- kinase] and Foxo3 [forkhead box protein O3]).
Importantly, most up- regulated pathways as well as 
overexpressed genes such as Tnf,(23) Nf- κB,(24) Bcl2,(25) 
Tlr4/9,(26) and pi3K(27) have been previously reported in 
relation to the progression of clinical and preclinical ste-
atohepatitis and liver fibrosis (Supporting Fig. S11B).
Dual Diet DRiVes 
FiBRogenesis anD 
tumoRigenesis
Epidemiological data suggest that the combination 
of alcohol and metabolic factors is associated with an 
increased risk of cirrhosis and cancer.(3) Therefore, we 
challenged mice to long- term DUAL feeding. Within 
52 weeks of DUAL diet, livers became extraordinarily 
enlarged, whitish- yellow in color, with pronounced scar 
tissue on the surface and multiple nodules in some, but 
not in all mice (Fig. 7A,B). Moreover, animals devel-
oped splenic enlargement (Supporting Fig.  S12A), 
and significant increases of plasma AST, ALT, LDH, 
and serum cholesterol (Supporting Fig.  S12B- E). 
Hematoxylin and eosin (H&E) and SR stainings 
demonstrated intense immune infiltration, significant 
fatty changes, extensive collagen deposition, and well- 
differentiated micronodules, surrounded by fibrotic 
connective tissue extending between portal regions, 
which overall indicated the stage of hepatic cirrho-
sis (Fig.  7C). Notably, we detected HSP70/HSP72 
and CK19 positive staining, a broadly used marker of 
hepatocellular carcinoma (HCC), inside the nodules 
(Fig.  7D). Nodules exhibit positive proliferating cell 
nuclear antigen (PCNA) nuclei staining, an indicator of 
Fig. 5. DUAL feeding leads to prominent hepatic fibrosis. (A) α- SMA western blot using β- actin as a loading control. Ratio between 
α- SMA and β- actin is calculated. (B) HSCs and fibrosis- related stainings in liver. Representative liver images stained with α- SMA (IHC), 
SR, and collagen I (IF). Scale bar = 100 µm. (C,D) Quantification of positive SR- stained and collagen I– stained areas after 23 weeks of 
treatment, respectively (SR, n = 3- 6; collagen I, n = 3- 4). (E). Fibrosis score assigned after 10 weeks and 23 weeks of feeding in all groups 
(n = 3- 7) (F) Respective collagen I (10 weeks and 23 weeks) and MCP1 (23 weeks) mRNA expression relative to GAPDH (n = 3- 
6). Values with different superscripts are significantly different from each other (P < 0.05), assessed by one- way ANOVA. Differences 
(P < 0.05) between time points (10 weeks vs. 23 weeks) for each pairing group were assessed by pairing one- way ANOVA and denoted as 
“#.” Abbreviation: MCP1, monocyte chemoattractant protein 1.
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proliferation and cell- cycle up- regulation. Consistently, 
cyclin E mRNA expression was increased in the liver 
tissue of DUAL mice (Supporting Fig. S13A,B).
To further study the effect of our DUAL model on 
tumor progression, male mice were administered a single 
dose of diethylnitrosamine (DEN) at the age of 14 days. 
Eight weeks later, DEN- treated mice were placed on a 
DUAL diet or control chow diet for 16 weeks (Supporting 
Fig.  S14A). Macroscopic evaluation identified that all 
mice fed with DUAL diet exhibited single or multiple 
tumor nodules larger than 0.5 cm (Fig. 8A,B). In con-
trast, only one out of nine mice developed DEN- induced 
nodule on chow treatment. Additionally, the DUAL diet 
also increased the hepatosomatic ratio, ALT, AST, and 
LDH in DEN- treated mice (Supporting Fig. S14B- E). 
Pathological examination (Fig.  8C) revealed well- 
circumscribed lesions with compressed adjacent paren-
chyma, loss of lobular architecture, and moderate fatty 
changes. All tumor nodules in DEN  +  DUAL mice 
showed strong nuclear expression of PCNA (Fig. 8D). 
Next, we assessed the characteristic tumor markers and 
found strong overexpression of HSP70/72 (Fig. 8E) and 
CK19 stainings (Supporting Fig. S14F) in the nodules 
of DEN + DUAL treated mice.
Taken together, our experimental model showed 
hepatic hyperplasia confirmed following histolog-
ical examination and significant up- regulation of 
HSP70/72, CK19, and cell proliferation (PCNA), pro-
viding evidence for the synergistic and tumor promot-
ing action of DUAL diet in DEN- induced early HCC.
Discussion
Over 2 billion people worldwide consume alcohol, 
and up to 75 million are diagnosed with  alcohol- use 
disorders and are at high risk of  ALD.(1) Moreover, 
modern societies have acquired unhealthy fast food 
habits that tremendously promote weight gain and, 
consequently, the development of MAFLD.(28,29)
The latest figures indicate that overweight affects 
from 30%- 70% of the population.(30) Thus, very likely, 
both dietary habits, alcohol drinking pattern, and high 
caloric consumption would overlap in one part of the 
population. Moreover, high caloric meals are often 
combined with mild and regular alcohol intake.(31) In 
fact, for patients with BMI over 35 kg/m2, the hepa-
totoxicity of alcohol doubles.(1)
Recent epidemiological and experimental evidence 
has highlighted the dangerous synergism of alcohol, 
obesity, and MS in the progression of chronic liver dis-
ease.(4- 6) One of these conditions is often predominant, 
with the other acting as a cofactor of morbi- mortality.(3)
Therefore, an appropriate animal model that faith-
fully reproduces a combined type of liver damage 
would definitely improve the understanding of the 
synergistic mechanism of alcohol and MS. In the cur-
rent study, we developed a physiological experimental 
murine model that mimics the human dietary habits 
by combining high fat,  high fructose,  high choles-
terol, Western- style diet with alcohol administration.
Although several hybrid models have been sug-
gested,(32,33) most of them have relevant limitations 
and do not fully mirror all physiological, metabolic, 
histologic, and common clinical features of human ste-
atohepatitis (Supporting Table  S7), including hepatic 
inflammation and advanced fibrosis.(8) The main reason 
is that animals naturally display strong aversion to alco-
hol. Therefore, if alcohol is incorporated in the drink-
ing water, mice drink much less than expected, which is 
sufficient to induce moderate clear steatosis but simply 
not high enough to cause significant liver damage.(9)
In our innovative model, we combined WD with 
EtOH in the drinking water sweetened by D- glucose. 
Fig. 6. Single- cell RNA- seq of liver tissue after 10 weeks of DUAL feeding. (A) The volcano plot was constructed using fold- change 
values and adjusted P values. The vertical blue lines corresponds to 2- fold up and down, and horizontal green line represents adjusted P 
value of 0.05. The red points indicate differentially expressed genes with statistical significance, and nonsignificant genes are in black. (B) 
Gene ontology enrichment analysis performed for up- regulated and down- regulated genes between C57BL/6 control diet and DUAL diet. 
The top 10 enriched the biological process, molecular function, and cellular component. The x- axis represents the P- value ranking, and the 
y- axis represents the gene ontology term. Red and blue bars indicate up- regulated and down- regulated gene ontology terms, respectively. 
(C) Overview of the protein– protein interaction network. The network was generated using the NetworkAnalyst. Color represents the 
expression of nodes. Specifically, red and green represent up- regulated and down- regulated nodes, respectively. The color gradient indicates 
the expression level. The size of the nodes indicates the degrees that the nodes connect to others. Abbreviations: Bcl2, B- cell lymphoma 2; 
Btk, Bruton tyrosine kinase; Csf1, Macrophage colony- stimulating factor 1; ERK, extracellular signal- regulated kinase; Foxo1, Forkhead 
Box O1; Fyn, Proto- oncogene tyrosine- protein kinase Fyn; GO, gene ontology; Irf8, Interferon Regulatory Factor 8; LogFC, fold change; 
MAPK, mitogen- activated protein kinase; NF- κB, Nuclear factor kappa B; Pi3k, Phosphoinositide 3- kinases; Plcg2, Phospholipase C 
Gamma 2; Ptgs2, Prostaglandin- Endoperoxide Synthase 2; Syk, Spleen Associated Tyrosine Kinase; TNF, tumor necrosis factor.
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Fig. 7. Advanced fibrosis and tumor development in DUAL diet as an end- point of metabolic disease. (A) Liver pictures after 52 weeks 
of feeding: control, DUAL, and DUAL with regenerative nodule. Fibrotic scars and nodules on the surface are marked with arrows. 
(B) Liver/BW ratio (%) (n = 5). (C) Representative pictures of H&E and SR stainings after 52 weeks: control, DUAL, and DUAL with 
regenerative nodule. Scale = 100 µm. (D) Representative pictures of Hsp70/72 and CK19 after 52 weeks treatment. Scale = 100 µm. Values 
with different superscripts are significantly different from each other (P < 0.05), assessed by one- way ANOVA.
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Fig. 8. DUAL diet + DEN injection as a model of rapid tumor progression. (A) Liver pictures of DEN and DEN + DUAL model. 
Tumor nodules are marked with arrows. (B) Number of tumor nodules > 0.5 cm per liver (n = 4- 9). (C- E) Representative pictures of 
H&E, Hsp70/72, and PCNA, respectively. Scale = 100 µm. Values with different superscripts are significantly different from each other 
(P < 0.05), assessed by one- way ANOVA.
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We used WD from the Amylin liver NASH study(16) 
as a combination of 40% fat, 22% fructose, and 2% 
cholesterol, resulting in relatively strong steatohepa-
titis. Moreover, glucose in the drinking water poten-
tiates absorption of fructose from the diet, whereas 
fructose catalyzes glucose uptake and storage in the 
liver, leading together to stronger harm.(34)
More importantly, by incorporating D- glucose in 
the water we overcome mouse aversion to alcohol. 
Sweetened water successfully masked the taste of alco-
hol, thus increasing alcohol intake. DUAL- fed ani-
mals consume 32.2 g/kg of alcohol daily. Hence, the 
relative risk of alcohol- associated cirrhosis increases in 
humans who drink more than 25 g/day.(35)
Additionally, the consumption of fatty WD further 
elevated EtOH intake. Previous reports suggested the 
existence of a positive correlation between EtOH and 
fat, whereby each nutrient stimulates the intake of 
the other. Within this synergistic vicious cycle, calorie 
intake can dramatically increase.(10)
Consequently, following initiation of the DUAL 
diet, mice started to gain weight and developed obesity, 
characterized by an increase in BMI. Over a period of 
23 weeks, the DUAL group became 19% heavier than 
the control group. Abdominal obesity is a predomi-
nant underlying risk factor for MS.(13) Simultaneously 
with obesity, DUAL animals developed dyslipidemia 
and hyperglycemia: altogether three important medical 
conditions of MS.(36) Hence, it is essential to mention 
that impaired fasting glycemia was not accompanied 
either by glucose intolerance or by insulin resistance 
in DUAL mice. In fact, the ITT area under the 
curve was significantly lower in animals treated with 
DUAL diet compared with controls. Nevertheless, 
the explanation for this phenomenon by enhanced 
insulin action is an obvious misinterpretation of the 
results. We believe that DUAL mice exhibited a defect 
in the counter- regulatory response to insulin in— 
particularly— gluconeogenesis.(37) In fact, RNA- seq 
data demonstrated that the level of glucose- 6 phos-
phatase was remarkably lower in the DUAL group.
Another key feature of the DUAL obesity is the 
remarkable damage of WAT: Hypertrophic adipocytes 
develop an inflammatory phenotype and crown- like 
structures, consisting of necrotic adipocytes. Adipocyte 
death and subsequent inflammation increase lip-
olysis, flux of lipids to the liver, production of pro- 
inflammatory cytokines, and significantly contribute to 
disease progression.(3,11) Previous animal studies showed 
that high- fat diet in combination with EtOH binge 
feeding synergistically induce liver injury by stimulat-
ing hepatocytes to produce chemokine (C- X- C motif ) 
ligand 1 (CXCL1), which subsequently promoted 
hepatic neutrophil recruitment.(38) RNA- seq data 
showed up- regulation of CXCL1 (up to 30 times) and 
concomitant pathways related to neutrophil- mediated 
immunity in the liver of DUAL animals.
Hence, hepatic steatosis induced by DUAL diet 
takes a short period of time. Due to the massive flux 
of FFAs into the liver, relatively poor  ß- oxidation 
and reduced TG secretion, lipids accumulate in large 
amounts already after 10 weeks of feeding and gradually 
increase over time. DUAL mice developed microvesic-
ular and macrovesicular steatosis with hepatocytes bal-
looning. Consequently, the increased accumulation of 
FFAs in the liver led to metabolism deregulation and 
the generation of oxidative stress, which triggered cell 
death, inflammation, and immune cell infiltration into 
the hepatic parenchyma.
Inflammatory cytokines, produced by immune cells 
(e.g., TNF- α), further activated HSCs and stimulated 
the production of collagen fibers and ECM deposition 
in the liver, leading to fibrogenesis.(39) Mice fed a DUAL 
diet exhibited steatohepatitis already after 10  weeks, 
whereas feeding for 23 weeks resulted in more fibrotic 
stage, particularly affecting the portal and bridging areas.
Notably, transcriptomic changes relevant to chronic 
liver diseases in humans were also demonstrated in 
DUAL mice, including (1) Btk, Csf1, Sfpi1, Irf8 and 
Syk, which play critical roles in the development and 
function of myeloid and lymphoid cells, associated with 
chronic inflammation(40- 43); (2) Bcl2, Ptgs2, Plcg2 and 
Fyn, which promote apoptosis and proliferation(25,44,45); 
and (3) Pi3k and Foxo1, which are master regulators of 
glucose/lipid homeostasis.(46,47) The up- regulation of 
TNF and NF- κB(24)  in DUAL animals entirely reca-
pitulated the pathogenesis of human- like steatohepati-
tis and correlated with disease progression to advanced 
fibrosis. Importantly, the activation of TLR4/9 indi-
cated that besides the direct toxic effect of alcohol and 
WD on the liver, the abnormal microbiome and the 
loss of intestinal barrier function may potentially con-
tribute to the pathogenesis in DUAL mice.(26,48)
DUAL mice were similar to human disease, not only 
in terms of initiation of steatohepatitis, but also in devel-
opment of cirrhosis and tumorigenesis. Thus, after 1 year 
of DUAL diet, animals demonstrated extensive collagen 
accumulation and micronodular cirrhotic changes.
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The reported DUAL diet additionally functions as an 
excellent tumor promoter for DEN- induced liver tum-
origenesis in mice. With this diet, preneoplastic nodules 
develop within only 26 weeks following DEN injection. 
This observation supports the importance of identifying 
patients with excess alcohol consumption and MS, as 
they are at a higher risk of liver- related cancer.
Altogether, our preclinical model induces the 
development of liver damage in the context of key 
risk factors for the human condition (e.g., alco-
hol consumption, obesity, MS), naturally mimicking 
human pathology and the progression to advanced 
liver fibrosis, cirrhosis, and end- stage tumorigenesis. 
Importantly, it is an easy, affordable, highly repro-
ducible, time- efficient diet that does not require any 
special skill or expensive equipment. Moreover, it is 
associated with no mortality even using long- term 
feeding, and as a mild procedure, it should be easily 
approved by ethical committees.
However, there are some limitations and meth-
odological difficulties in our DUAL model. First, 
according to our observations, as typical nocturnal 
animals, mice consumed significant amounts of EtOH 
in the drinking water primarily during the dark cycle. 
Hence, given the fast metabolic capacity of mice, on 
the following morning their blood alcohol level levels 
drop significantly. Therefore, we calculated the daily 
amount of consumed alcohol based on the volume of 
the water drunk from the bottle. Second, we tested 
our model on male and female mice. Independently of 
gender, all mice developed steatohepatitis and fibro-
sis, and advanced cirrhotic changes. Nonetheless, the 
phenotype in male mice was slightly stronger, includ-
ing a more elevated BMI, more pronounced steato-
sis, and moderately increased ALT (data not showed). 
However, we dealt with some difficulties with the 
housing of male mice. Food intake was negatively 
affected by the subordination, raising concerns about 
welfare, alcohol consumption, and negatively impacted 
research validity. Hence, according to our experience, 
the only possibility for male mice is individual hous-
ing (for DUAL diet and the corresponding control 
groups).
Finally, lack of clinical studies with tissue of patients 
with DUAL alcoholic and metabolic- associated ste-
atohepatitis was a limitation of our study. Moreover, 
there were major methodological concerns about the 
existing studies, as many reports failed to consider 
the pattern and type of alcohol use and/or did not 
separate between lifetime and current abstainers. In 
addition, underreporting of alcohol use is a major 
concern, particularly when assessing patients who are 
aware of their liver disease.(49,50)
Altogether, DUAL alcoholic and MAFLD remains 
as not well- explored area of great interest, despite the 
increased number of affected patients. Our innovative 
preclinical DUAL model can be a valuable toolbox, 
as it mimics all histological, metabolic, transcriptomic 
gene signatures of human disease, thereby contribut-
ing to the development of very much needed thera-
peutic targets (Supporting Fig. S13).
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